Lei Sun

Dr. Lei Sun

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2024 in Journal of Experimental & Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
FRFei Ren
Fei Ren
QFQian Fei
Qian Fei
KQKun Qiu
Kun Qiu
YZYuanjie Zhang
Yuanjie Zhang
HZHeyang Zhang
Heyang Zhang
LSLei Sun
Lei Sun
Lung cancer stands as the most prevalent form of cancer globally, posing a significant threat to human well-being. Due to the lack of effective and accurate early diagnostic methods, many patients are diagnosed with advanced lung cancer. Although surgical resection is still a potential means of eradicating lung cancer, patients with advanced lung cancer usually miss the best chance for surgical treatment, and even after surgical resection patients may still experience tumor recurrence. Additionally, chemotherapy, the mainstay of treatment for patients with advanced lung cancer, has the potential to be chemo-resistant, resulting in poor clinical outcomes. The emergence of liquid biopsies has garnered considerable attention owing to their noninvasive nature and the ability for continuous sampling. Technological advancements have propelled circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), extracellular vesicles (EVs), tumor metabolites, tumor-educated platelets (TEPs), and tumor-associated antigens (TAA) to the forefront as key liquid biopsy biomarkers, demonstrating intriguing and encouraging results for early diagnosis and prognostic evaluation of lung cancer. This review provides an overview of molecular biomarkers and assays utilized in liquid biopsies for lung cancer, encompassing CTCs, ctDNA, non-coding RNA (ncRNA), EVs, tumor metabolites, TAAs and TEPs. Furthermore, we expound on the practical applications of liquid biopsies, including early diagnosis, treatment response monitoring, prognostic evaluation, and recurrence monitoring in the context of lung cancer.

15 July 2025 in Cancer Letters
Verified
Journal Article
Open access
CWCen Wu
Cen Wu
TXTianhua Xu
Tianhua Xu
HZHeyang Zhang
Heyang Zhang
YHYile Hu
Yile Hu
JJJinghua Jiao
Jinghua Jiao
LSLei Sun
Lei Sun
The tumor microenvironment (TME), regulated by both intrinsic oncogenic factors and immune metabolic processes, has become an increasing focus of research in recent years. Typical features of the TME include hypoxia, metabolic dysregulation, and immunosuppression. Metabolic reprogramming provides tumors with energy and biosynthetic compounds to meet the nutritional requirements for proliferation. Meanwhile, immune metabolism influences tumor cells to shape the tumor immunosuppressive microenvironment by altering immune cell function and phenotype. Tumor hypoxia signaling specifically fosters the development of immunosuppressive TME by regulating immune metabolism, which, in turn, supports the progression of malignant tumors through modulation of their biological behaviors. This review comprehensively explores the metabolic regulation of hypoxia and immune metabolism during the dynamic evolution of tumor-adapted TME. In the context of the intricate interplay between hypoxia and immunometabolism, the prospects and challenges associated with immunometabolism in the clinical management of tumors are systematically addressed.

19 December 2023 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
QHQilin Hu
Qilin Hu
LCLujun Chen
Lujun Chen
KLKerui Li
Kerui Li
RLRuotong Liu
Ruotong Liu
LSLei Sun
Lei Sun
THTAO HAN
TAO HAN
Over the past decades, liquid biopsy, especially circulating tumor DNA (ctDNA), has received tremendous attention as a noninvasive detection approach for clinical applications, including early diagnosis of cancer and relapse, real-time therapeutic efficacy monitoring, potential target selection and investigation of drug resistance mechanisms. In recent years, the application of next-generation sequencing technology combined with AI technology has significantly improved the accuracy and sensitivity of liquid biopsy, enhancing its potential in solid tumors. However, the increasing integration of such promising tests to improve therapy decision making by oncologists still has complexities and challenges. Here, we propose a conceptual framework of ctDNA technologies and clinical utilities based on bibliometrics and highlight current challenges and future directions, especially in clinical applications such as early detection, minimal residual disease detection, targeted therapy, and immunotherapy. We also discuss the necessities of developing a dynamic field of translational cancer research and rigorous clinical studies that may support therapeutic strategy decision making in the near future.

1 April 2020 in Cell Cycle
Verified
Journal Article
Closed access
JGJia Gu
Jia Gu
THTao Han
Tao Han
LSLei Sun
Lei Sun
AYAihui Yan
Aihui Yan
XJXuejun Jiang
Xuejun Jiang
Numerous researches show that MicroRNAs (miRNAs) participate in tumorigenesis, progression, recurrence and drug resistance of malignant tumors, including laryngocarcinoma. miR-552 works as an oncogene in both colorectal cancer and liver cancer. However, the potential role of miR-552 in laryngocarcinoma is unknown. Herein, we for first found that miR-552 expression was upregulated in laryngocarcinoma tissues compared with their normal controls. Moreover, miR-552 expression was also increasing in the laryngocarcinoma cells. miR-552 interference inhibited the proliferation and metastasis of laryngocarcinoma cells in vitro and in vivo. Mechanically, bioinformatics and luciferase reporter analysis identified p53 as a direct target of miR-552. miR-552 knockdown upregulated the p53 mRNA and protein expression in laryngocarcinoma cells. miR-552 expression was negatively associated with p53 expression in laryngocarcinoma tissues. More importantly, the p53 siRNA or p53 overexpression virus abrogated the discrepancy of growth and metastasis capacity between miR-552 interference laryngocarcinoma cells and control cells.

19 June 2025 in npj Precision Oncology
Verified
Journal Article
Open access
PDF file
MZMin Zhou
Min Zhou
MLMengqing Liu
Mengqing Liu
YHYile Hu
Yile Hu
ZXZhe Xu
Zhe Xu
LCLutong Cai
Lutong Cai
LSLei Sun
Lei Sun
Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality, with immunotherapy proving effective only in a subset of patients, highlighting the urgent need for improved biomarkers and therapeutic targets. This study explored regulatory T cell (Treg) metabolism-related genes in NSCLC and established a seven-gene prognostic signature (TIMP1, BIRC3, G0S2, PRKCB, PDE4B, CD52, and ACP5) through multi-omics analysis. The model stratified patients into high- and low-risk groups exhibiting distinct immune profiles and drug sensitivities. Clinical validation confirmed that elevated BIRC3 and G0S2 expression correlated with poorer prognosis, while functional assays demonstrated that G0S2 inhibition suppressed tumour progression and reduced Treg infiltration in vivo. These findings position G0S2 as a promising biomarker for immunotherapy response and a potential therapeutic target, providing insights into Treg-mediated immune regulation and advancing personalized NSCLC treatment strategies.

18 March 2024 in IEEE Transactions on Instrumentation and Measurement
Verified
Journal Article
Closed access
HLHao Liu
Hao Liu
SZShenglin Zhang
Shenglin Zhang
YYYongming Yang
Yongming Yang
LSLei Sun
Lei Sun
ZSZhan Song
Zhan Song
SXShun Xu
Shun Xu
Interventional bronchoscopy is a minimally invasive procedure used to diagnose and treat peripheral pulmonary nodules. Bronchoscope navigation is one of the crucial technologies for guiding the biopsy pose with precision. However, electromagnetic navigation is vulnerable to respiratory motion and tissue displacement, while visual navigation of continuous frames can become unstable in blurred scenes. To overcome these challenges, we propose a robust two-stage hybrid navigation framework that integrates spatial geometry awareness with hybrid update block. Our spatial-aware network leverages the strength of normal and gradient losses to deal with small structural fluctuations and stepped edges. It is trained on a synthetic scenario dataset and can be generalized to in-vivo scenes. Using the initial pose from electromagnetic keypoint registration, a hybrid update block employs the spatial-aware network as a reliable and content-rich feature comparator to perform efficient optimal pose search with swarm intelligence. Positional and orientational accuracy of our method has been verified and compared with recent SOTA methods in phantom and animal experiments. Both quantitative and qualitative results demonstrate that we provide a promising method for improving the accuracy and robustness of bronchoscopic navigation.